"Chlorobenzenes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Aromatic organic compounds with the chemical formula C6H5Cln.
| Descriptor ID |
D002722
|
| MeSH Number(s) |
D02.455.426.559.389.261 D02.455.526.439.202
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Chlorobenzenes".
Below are MeSH descriptors whose meaning is more specific than "Chlorobenzenes".
This graph shows the total number of publications written about "Chlorobenzenes" by people in this website by year, and whether "Chlorobenzenes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 1 | 0 | 1 |
| 2017 | 3 | 0 | 3 |
| 2018 | 3 | 3 | 6 |
| 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Chlorobenzenes" by people in Profiles.
-
Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp14 RNA cap methyltransferase. Biochem J. 2021 07 16; 478(13):2481-2497.
-
A new horizon for the old antibacterial drug clofoctol. Drug Discov Today. 2021 05; 26(5):1302-1310.
-
Human exposure to bisphenol AF and diethylhexylphthalate increases susceptibility to develop differentiated thyroid cancer in patients with thyroid nodules. Chemosphere. 2019 Mar; 218:885-894.
-
The Efficacy and Safety of Once-daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-daily Budesonide/Formoterol in a Subgroup of Patients from China with Symptomatic COPD at Risk of Exacerbations (FULFIL Trial). COPD. 2018 Jun-Aug; 15(4):334-340.
-
Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting ß2-agonists (ICS/LABA) in patients with uncontrolled asthma: An open-label, randomized, controlled trial. Respir Med. 2018 08; 141:111-120.
-
Discovery and evolution of aloperine derivatives as novel anti-filovirus agents through targeting entry stage. Eur J Med Chem. 2018 Apr 10; 149:45-55.
-
COPD 2017: A Year in Review. COPD. 2018 04; 15(2):118-122.
-
Glucocorticoid Receptor Nuclear Translocation in CD4 T Cells from Severe and Moderate Asthmatic Patients Treated with Fluticasone/Vilanterol. Iran J Allergy Asthma Immunol. 2018 Feb; 17(1):1-8.
-
Fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease. Expert Rev Respir Med. 2017 12; 11(12):955-967.
-
Pharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchi. Eur J Pharmacol. 2017 Oct 05; 812:147-154.